Desmopressin

What it's for

Desmopressin is a synthetic analog of vasopressin modified for greater V2 selectivity and longer action. Treats central diabetes insipidus, primary nocturnal enuresis, and increases factor VIII/von Willebrand factor (a clotting helper) in mild hemophilia A and type 1 von Willebrand disease as labeled.

What it does for the body

Treats central diabetes insipidus, primary nocturnal enuresis, and increases factor VIII/von Willebrand factor (a clotting helper) in mild hemophilia A and type 1 von Willebrand disease as labeled. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.

What it targets

V2 receptors (lock-and-key landing spots on cells) activation in kidney concentrates urine; in endothelium it releases von Willebrand factor (a clotting helper) and factor VIII. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.

Research context

Bottom line for readers: Desmopressin has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.

Studied for (literature interest)

• Heart research interest (educational tag)

Cautions (educational)

• Educational only — not medical advice.
• DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.

Citations / starters

• FDA search: Desmopressin — FDA.gov search
• ClinicalTrials.gov search: Desmopressin — U.S. clinical trials registry
• Drugs@FDA search: Desmopressin — FDA drug database (if approved)
• PubMed search: Desmopressin — NCBI PubMed
• PubMed Central search: Desmopressin — NCBI PMC

Reference

No ref on file.